Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study.
Deharo P, Pons C, Pankert M, Bonnet G, Quilici J, Grosdidier C, Beguin S, Morange P, Alessi MC, Bonnet JL, Cuisset T. Deharo P, et al. Among authors: beguin s. Int J Cardiol. 2013 Oct 12;168(5):5004-5. doi: 10.1016/j.ijcard.2013.07.121. Epub 2013 Jul 31. Int J Cardiol. 2013. PMID: 23915522 No abstract available.
Basic residues of human group IIA phospholipase A2 are important for binding to factor Xa and prothrombinase inhibition comparison with other mammalian secreted phospholipases A2.
Mounier CM, Luchetta P, Lecut C, Koduri RS, Faure G, Lambeau G, Valentin E, Singer A, Ghomashchi F, Béguin S, Gelb MH, Bon C. Mounier CM, et al. Among authors: beguin s. Eur J Biochem. 2000 Aug;267(16):4960-9. doi: 10.1046/j.1432-1327.2000.01523.x. Eur J Biochem. 2000. PMID: 10931177 Free article.
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T. Grosdidier C, et al. Among authors: beguin s. Am J Cardiol. 2013 Apr 1;111(7):985-90. doi: 10.1016/j.amjcard.2012.12.013. Epub 2013 Jan 19. Am J Cardiol. 2013. PMID: 23340030
Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome.
Cuisset T, Cayla G, Quilici J, Pankert M, Deharo P, Bonnet G, Grosdidier C, Beguin S, Morange P, Bonnet JL, Alessi MC. Cuisset T, et al. Among authors: beguin s. Int J Cardiol. 2013 Oct 3;168(3):2988-9. doi: 10.1016/j.ijcard.2013.04.052. Epub 2013 Apr 30. Int J Cardiol. 2013. PMID: 23642612 No abstract available.
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, Pankert M, Beguin S, Lambert M, Morange PE, Bonnet JL, Alessi MC. Cuisset T, et al. Among authors: beguin s. JACC Cardiovasc Interv. 2013 Aug;6(8):854-63. doi: 10.1016/j.jcin.2013.04.009. JACC Cardiovasc Interv. 2013. PMID: 23968703 Free article.
CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome.
Cuisset T, Loosveld M, Morange PE, Quilici J, Moro PJ, Saut N, Gaborit B, Castelli C, Beguin S, Grosdidier C, Fourcade L, Bonnet JL, Alessi MC. Cuisset T, et al. Among authors: beguin s. JACC Cardiovasc Interv. 2012 Dec;5(12):1280-7. doi: 10.1016/j.jcin.2012.07.015. JACC Cardiovasc Interv. 2012. PMID: 23257377 Free article.
131 results